Delivery Order SPE2DB20D1100-SPE2DB25FD8D5
- Not listed
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order contract award from the Defense Logistics Agency's Medical Supply Chain for the supply of CellCept 500 mg tablets (500-count bottles). The contract, awarded May 12, 2025, carries a firm fixed price ceiling value of $8,316.17 with an ultimate completion date of May 13, 2025. This delivery order represents a non-set-aside, competitively awarded procurement and is classified as a child contract under...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency (DLA) on July 16, 2025, for CellCept 250 mg capsules (100-count units) with a ceiling value of $17,152.58. This firm fixed-price delivery order, which is due for completion by July 17, 2025, represents a non-set-aside competitive award under the broader pharmaceutical supply framework. The contract will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of CellCept 500 mg tablets (100-count packages) under a firm fixed-price contract valued at $4,349.15. This is a non-set-aside competitive award with an ultimate completion date of August 26, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, a leading pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on June 2, 2025, for CellCept 200 mg/mL oral suspension (160 mL). This firm fixed-price contract, valued at $1,093.31, represents a non-competitive set-aside delivery order with an ultimate completion date of June 3, 2025. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $29,003.35 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of CellCept 500 mg tablets (500-count units). This is a firm fixed price, non-set-aside contract with a completion date of August 6, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of CellCept 500 mg tablets (500-count bottles) under a firm fixed-price contract with a ceiling value of $13,051.42. The delivery order, which is not set-aside, is scheduled for completion by July 31, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $33,203.38 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500-count units). This competitive, firm fixed-price delivery order was executed on August 21, 2025, with an ultimate completion date of August 22, 2025. The contract does not carry a set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (100-count units) valued at $7,854.18. The award was made on May 6, 2025, with an ultimate completion date of May 7, 2025, under a firm fixed-price delivery order arrangement. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate...
- This is a $16,028.49 firm fixed-price delivery order awarded to AmerisourceBergen Drug Corp by the Defense Logistics Agency (DLA) on December 3, 2024. The contract provides for the delivery of 4,566,590,738 units of CellCept 500 mg tablets by December 4, 2024. AmerisourceBergen, a major pharmaceutical distributor, is the prime contractor with no set-aside designation indicated. This contract award is part of AmerisourceBergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the...
- The Defense Logistics Agency awarded a $31,747.33 delivery order to AmerisourceBergen Drug Corp for 100-count bottles of CellCept 500 mg tablets, a pharmaceutical product used primarily for immunosuppression in transplant patients and autoimmune conditions. The contract, issued on June 2, 2025, carries a firm fixed price structure with an ultimate completion date of June 3, 2025, and represents a non-set-aside competitive award. Performance will be executed at the vendor's corporate office...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD8D5Delivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a competitively awarded delivery order (Contract No. 4568982464) by the Defense Logistics Agency on August 4, 2025, for the supply of CellCept 500 mg tablets in a quantity of 100 units. This firm fixed-price delivery order carries a ceiling value of $7,817.19 and is scheduled for ultimate completion by August 5, 2025. The contract carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The delivery order supports the Defense Logistics Agency's Medical Supply Chain in providing critical pharmaceutical products to military healthcare systems and federal medical procurement needs. CellCept (mycophenolate mofetil) is an immunosuppressive medication commonly used in organ transplant recipients and certain autoimmune conditions. This award demonstrates AmerisourceBergen's continued capability to fulfill federal medical supply requirements through competitive procurement processes and reflects the company's role as a critical vendor in supporting military and veteran healthcare operations globally through the DLA's comprehensive pharmaceutical prime vendor program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.8k | 8/4/25 |